Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma

被引：1
|
作者：
Abramson, Jeremy S. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
来源：
TRANSPLANTATION AND CELLULAR THERAPY | 2022年 / 28卷 / 10期
关键词：
AXICABTAGENE CILOLEUCEL; TISAGENLECLEUCEL; OUTCOMES; MULTICENTER;
D O I：
10.1016/j.jtct.2022.09.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：621 / 622
页数：2
相关论文
共 50 条
  • [11] Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma
    Ahmed, Gulrayz
    Furqan, Fateeha
    Nasrollahi, Elham
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 705 - 715
  • [12] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [13] Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
    Armand, Philippe
    Rodig, Scott
    Melnichenko, Vladimir
    Thieblemont, Catherine
    Bouabdallah, Kamal
    Tumyan, Gayane
    Ozcan, Muhit
    Portino, Sergio
    Fogliatto, Laura
    Caballero, Maria D.
    Walewski, Jan
    Gulbas, Zafer
    Ribrag, Vincent
    Christian, Beth
    Perini, Guilherme Fleury
    Salles, Gilles
    Svoboda, Jakub
    Zain, Jasmine
    Patel, Sanjay
    Chen, Pei-Hsuan
    Ligon, Azra H.
    Ouyang, Jing
    Neuberg, Donna
    Redd, Robert
    Chatterjee, Arkendu
    Balakumaran, Arun
    Orlowski, Robert
    Shipp, Margaret
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) : 3291 - +
  • [14] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [15] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
  • [16] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
    Ruminy, Philippe
    Rainville, Vinciane
    Mareschal, Sylvain
    Etancelin, Pascaline
    Joly, Berangere
    Picquenot, Jean-Michel
    Bastard, Christian
    Tilly, Herve
    Jardin, Fabrice
    BLOOD, 2012, 120 (21)
  • [17] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [18] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [19] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [20] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
12345